Carbapenemase-producing Enterobacterales outbreak: Another dark side of COVID-19

Éric Farfour(European Foundation for Clinical Nanomedicine), Philippe Lesprit(Hôpital Foch), Laurent Dortet(Inserm), Rémy A. Bonnin(Inserm), Marc Vasse(Hôpital Foch), F. Karnycheff(Hôpital Foch), Morgan Le Guen(Hôpital Foch), Marion Lecuru(Hôpital Foch), Charles Cerf(Hôpital Foch)

American Journal of Infection Control

October 1, 2020

10.1016/j.ajic.2020.09.015

Cited by 70

Related Papers

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

|Science|2020|2.9k

Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread

|Nature Microbiology|2019|817

Worldwide Dissemination of the NDM-Type Carbapenemases in Gram-Negative Bacteria

|BioMed Research International|2014|485

Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation

|BMC Cancer|2019|362

Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study

|The Lancet Respiratory Medicine|2021|257